The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer.
Jangsoon LeeKumiko KidaJiwon KohHuey LiuGaniraju C ManyamYoung Jin GiDileep R RampaAsha S MultaniJing WangGitanjali JayachandranDae-Won LeeJames M ReubenAysegul SahinLei HuoDebu TripathySeock-Ah ImNaoto T UenoPublished in: Journal of experimental & clinical cancer research : CR (2024)
The DNA repair pathways contribute to HER2-directed ADC resistance. Our data justify exploring the combination treatment of T-DXd with DNA repair-targeting drugs to treat HER2-directed ADC-resistant HER2+ breast cancer in clinical trials.
Keyphrases
- dna repair
- dna damage
- cancer therapy
- clinical trial
- dna damage response
- diffusion weighted imaging
- diffusion weighted
- electronic health record
- epidermal growth factor receptor
- drug delivery
- randomized controlled trial
- big data
- magnetic resonance imaging
- oxidative stress
- machine learning
- combination therapy
- magnetic resonance
- computed tomography
- artificial intelligence
- replacement therapy
- breast cancer risk
- tyrosine kinase